Antonio Carletto
Overview
Explore the profile of Antonio Carletto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopalco G, Morrone M, Atzeni F, Bazzani C, Bianchi F, Cantatore F, et al.
Ther Adv Musculoskelet Dis
. 2025 Feb;
17:1759720X251315138.
PMID: 39897378
Background: Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU's usefulness in...
2.
Sebastiani M, Lepri G, Iannone C, Bozzalla Cassione E, Guggino G, Lo Monaco A, et al.
J Rheumatol
. 2024 Dec;
PMID: 39681380
Objective: Some concerns remain about the safety of nintedanib in patients with rheumatoid arthritis-related interstitial lung disease (RA-ILD), such as in the presence of comorbidities or in combination with biologic,...
3.
Ramonda R, Lorenzin M, Chimenti M, Atzeni F, Semeraro A, DAngelo S, et al.
Arthritis Res Ther
. 2024 Sep;
26(1):172.
PMID: 39342310
Objectives: to evaluate over a 48-month follow-up period the: 1) long-term effectiveness and safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA and DAPSA...
4.
Adami G, Bixio R, Virelli G, Galvagni I, Mastropaolo F, Morciano A, et al.
Rheumatology (Oxford)
. 2024 Aug;
PMID: 39167121
Background: Glucocorticoid sparing in rheumatoid arthritis (RA) treatment is crucial to minimizing adverse effects associated with long-term use. Janus kinase inhibitors (JAKi) could potentially offer a more potent glucocorticoid-sparing effect...
5.
Ramonda R, Lorenzin M, Chimenti M, DAngelo S, Marchesoni A, Selmi C, et al.
Front Immunol
. 2024 Jul;
15():1435599.
PMID: 39076975
Objectives: This study aims to evaluate in a real-life Italian multicenter cohort of axial spondyloarthritis (axSpA) (1) the 4-year effectiveness and safety of secukinumab, (2) the drug retention rate (DRR),...
6.
Bixio R, Bonetto C, Fracassi E, Ristic B, Mastropaolo F, Pacenza G, et al.
Clin Exp Rheumatol
. 2024 Jan;
42(5):1015-1019.
PMID: 38294018
Objectives: Fatigue is a common comorbidity in patients with axial spondyloarthritis (axSpA), often reported also by those in clinical remission or with moderate disease activity. The aim of this study...
7.
Ristic B, Carletto A, Fracassi E, Pacenza G, Zanetti G, Pistillo F, et al.
J Psychosom Res
. 2023 Oct;
175:111512.
PMID: 37844390
Objectives: This study aimed to compare the health-related quality of life scores among rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis and to evaluate socio-demographic and clinical determinantes of quality of life...
8.
Luchetti Gentiloni M, Paci V, Carletto A, Zabotti A, Ramonda R, Chimenti M, et al.
Arthritis Res Ther
. 2023 Oct;
25(1):196.
PMID: 37821952
Background: Upadacitinib (UPA) is a selective JAK inhibitor recently approved for the treatment of psoriatic arthritis (PsA). In this post-approval study, we aimed to evaluate the effectiveness and safety of...
9.
Scagnellato L, Collesei A, Doria A, Cozzi G, Lorenzin M, Atzeni F, et al.
Clin Exp Rheumatol
. 2023 Aug;
42(1):104-114.
PMID: 37650298
Objectives: We aimed to investigate the effectiveness of tumour necrosis factor inhibitors (TNFi), anti-interleukin-17 or interleukin-12/23 monoclonal antibodies (anti-IL) on comorbidities in a cohort of patients with spondyloarthritis (SpA), using...
10.
Venerito V, Manfredi A, Carletto A, Gentileschi S, Atzeni F, Guiducci S, et al.
J Clin Med
. 2023 Feb;
12(3).
PMID: 36769604
Background: The aim of this multicenter retrospective study was to investigate the effectiveness and safety of the available JAK-inhibitors (JAKi) in patients with rheumatoid arthritis (RA) and interstitial lung disease...